Case report: recurrent pituitary adenoma has increased load of somatic variants.
NFPA
Pituitary adenoma exome sequencing
Recurrent pituitary adenoma
Tumour variant analysis
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
29 Jan 2020
29 Jan 2020
Historique:
received:
13
03
2019
accepted:
16
01
2020
entrez:
31
1
2020
pubmed:
31
1
2020
medline:
24
11
2020
Statut:
epublish
Résumé
Pituitary adenomas (PA) have an increased potential for relapse in one to 5 years after resection. In this study, we investigated the genetic differences in genomic DNA of primary and rapidly recurrent tumours in the same patient to explain the causality mechanisms of PA recurrence. The patient was a 69-year-old female with non-functional pituitary macroadenoma with extension into the left cavernous sinus (Knosp grade 2) who underwent craniotomy and partial resection in August 2010. Two years later, the patient had prolonged tumour growth with an essential suprasellar extension (Knosp grade 2), and a second craniotomy with partial tumour resection was performed in September 2012. In both tumours, the KI-67 level was below 1.5%. Exome sequencing via semiconductor sequencing of patient germline DNA and somatic DNA from both tumours was performed. Tmap alignment and Platypus variant calling were performed followed by variant filtering and manual review with IGV software. We observed an increased load of missense variants in the recurrent PA tumour when compared to the original tumour. The number of detected variants increased from ten to 26 and potential clonal expansion of four variants was observed. Additionally, targeted SNP analysis revealed five rare missense SNPs with a potential impact on the function of the encoded proteins. In this case study, an SNP located in HRAS is the most likely candidate inducing rapid PA progression. The relapsed PA tumour had a higher variation load and fast tumour recurrence in this patient could be caused by clonal expansion of the leftover tumour tissue.
Sections du résumé
BACKGROUND
BACKGROUND
Pituitary adenomas (PA) have an increased potential for relapse in one to 5 years after resection. In this study, we investigated the genetic differences in genomic DNA of primary and rapidly recurrent tumours in the same patient to explain the causality mechanisms of PA recurrence.
CASE PRESENTATION
METHODS
The patient was a 69-year-old female with non-functional pituitary macroadenoma with extension into the left cavernous sinus (Knosp grade 2) who underwent craniotomy and partial resection in August 2010. Two years later, the patient had prolonged tumour growth with an essential suprasellar extension (Knosp grade 2), and a second craniotomy with partial tumour resection was performed in September 2012. In both tumours, the KI-67 level was below 1.5%. Exome sequencing via semiconductor sequencing of patient germline DNA and somatic DNA from both tumours was performed. Tmap alignment and Platypus variant calling were performed followed by variant filtering and manual review with IGV software. We observed an increased load of missense variants in the recurrent PA tumour when compared to the original tumour. The number of detected variants increased from ten to 26 and potential clonal expansion of four variants was observed. Additionally, targeted SNP analysis revealed five rare missense SNPs with a potential impact on the function of the encoded proteins.
CONCLUSIONS
CONCLUSIONS
In this case study, an SNP located in HRAS is the most likely candidate inducing rapid PA progression. The relapsed PA tumour had a higher variation load and fast tumour recurrence in this patient could be caused by clonal expansion of the leftover tumour tissue.
Identifiants
pubmed: 31996211
doi: 10.1186/s12902-020-0493-x
pii: 10.1186/s12902-020-0493-x
pmc: PMC6988340
doi:
Substances chimiques
Genetic Markers
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17Subventions
Organisme : European Regional Development Fund
ID : 1.1.1.1/16/A/066
Références
PLoS One. 2012;7(3):e33289
pubmed: 22413011
J Clin Endocrinol Metab. 2011 Jun;96(6):1633-41
pubmed: 21470998
J Epidemiol. 2018 Aug 5;28(8):353-360
pubmed: 29576601
Eur J Endocrinol. 2016 Aug;175(2):145-53
pubmed: 27185868
PLoS One. 2017 Oct 4;12(10):e0185826
pubmed: 28977029
Cell Res. 2016 Nov;26(11):1255-1259
pubmed: 27670697
Nature. 2004 Apr 29;428(6986):950-5
pubmed: 15057245
Eur J Endocrinol. 2016 Mar;174(3):363-72
pubmed: 26701869
Nucleic Acids Res. 2018 Jan 4;46(D1):D754-D761
pubmed: 29155950
Case Rep Endocrinol. 2018 Apr 29;2018:5027859
pubmed: 29854488
Braz J Med Biol Res. 2012 Sep;45(9):851-5
pubmed: 22782554
Pituitary. 2009;12(1):80-6
pubmed: 18350381
J Clin Endocrinol Metab. 2017 Jun 1;102(6):1889-1897
pubmed: 28323946
J Endocrinol. 2017 Dec;235(3):R101-R116
pubmed: 28835453
Chin Med J (Engl). 1998 Oct;111(10):891-4
pubmed: 11189233
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Science. 2014 Oct 10;346(6206):256-9
pubmed: 25301631
Pituitary. 2012 Mar;15(1):71-83
pubmed: 21918830
Pituitary. 2009;12(3):165-9
pubmed: 18642089
J Neurosurg. 1990 Nov;73(5):731-5
pubmed: 2213163
J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75
pubmed: 16968795
Lung Cancer. 2018 Jul;121:54-60
pubmed: 29858028
Nat Genet. 2015 Jan;47(1):31-8
pubmed: 25485838
J Clin Endocrinol Metab. 2013 Apr;98(4):E796-800
pubmed: 23450047
J Clin Endocrinol Metab. 2010 Jan;95(1):13-7
pubmed: 19890024
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):E2490-9
pubmed: 23766371
Exp Cell Res. 2012 Feb 15;318(4):299-310
pubmed: 22182599
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Genome Res. 2012 Aug;22(8):1525-32
pubmed: 22585873
Cell. 2017 Nov 16;171(5):1042-1056.e10
pubmed: 29056344
Endocr Relat Cancer. 2009 Mar;16(1):301-10
pubmed: 18852163
Cancer Res Treat. 2017 Jan;49(1):161-167
pubmed: 27384156
Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):10914-21
pubmed: 7902574
Pituitary. 2011 Sep;14(3):217-21
pubmed: 21170595
Head Neck Pathol. 2014 Jun;8(2):146-50
pubmed: 24277618
Am J Hum Genet. 2017 May 4;100(5):817-823
pubmed: 28413019
J Clin Endocrinol Metab. 2015 Oct;100(10):3918-27
pubmed: 26280510
J Cell Sci. 2016 Apr 1;129(7):1287-92
pubmed: 26985062
Oncol Lett. 2018 Jun;15(6):9413-9419
pubmed: 29844832
Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82
pubmed: 19650784
Clin Cancer Res. 2017 Apr 1;23(7):1841-1851
pubmed: 27707790